Self appraisal report for Year (2021-22)

Auditor Agency:

Ministry Name: Ministry of Chemicals & Fertilizers

Department Name: Department of Pharmaceuticals

Public Authority Name: Department of Pharmaceuticals

Sr. No	Details of disclosure	Category	Marks	Obtained Mark	Remarks	Auditor Category	Auditor Marks	Auditor Remarks/URL
1	Organisation and Function				_			
1.1	Particulars of its organisation, functions a	nd duties[Section	on 4(1)(b)(i)]	F			F
1.1.1	Name and address of the Organization	Fully Met	1.28	1.28	https://pharma ceuticals.gov. n/proactive- disclosure		1.28	https://pharma ceuticals.gov.i n/proactive- disclosure
1.1.2	Head of the organization	Fully Met	1.28	1.28	https://pharma ceuticals.gov. n/proactive- disclosure		1.28	https://pharma ceuticals.gov.i n/proactive- disclosure
1.1.3	Vision, Mission and Key objectives	Fully Met	1.28	1.28	https://pharma ceuticals.gov. n/about- department	•	1.28	https://pharma ceuticals.gov.i n/about- department
1.1.4	Function and duties	Fully Met	1.28	1.28	https://pharma ceuticals.gov. n/business- allocation		1.28	https://pharma ceuticals.gov.i n/business- allocation
1.1.5	Organization Chart	Fully Met	1.28	1.28	https://pharma ceuticals.gov. n/organisation chart-0		1.28	https://pharma ceuticals.gov.i n/organisation- chart-0

Sr. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
1.1.6	Any other details-the genesis, inception, formation of the department and the HoDs from time to time as well as the committees/ Commissions constituted from time to time have been dealt	Fully Met	1.28	1.28	https://pharma ceuticals.gov.i n/agencies-un der- department	Fully Met	1.28	https://pharma ceuticals.gov.i n/agencies-un der- department
1.2	Power and duties of its officers and employee	es[Section 4	(1) (b)(ii)]					
1.2.1	Powers and duties of officers (administrative, financial and judicial)	Fully Met	1.54	1.54	https://pharma ceuticals.gov.i n/proactive- disclosure		1.54	https://pharma ceuticals.gov.i n/proactive- disclosure
1.2.2	Power and duties of other employees	Fully Met	1.54	1.54	https://pharma ceuticals.gov.i n/proactive- disclosure	•	1.54	ОК
1.2.3	Rules/ orders under which powers and duty are derived and	Fully Met	1.54	1.54	https://pharma ceuticals.gov.i n/proactive- disclosure		1.54	ОК
1.2.4	Exercised	Fully Met	1.54	1.54	https://pharma ceuticals.gov.i n/proactive- disclosure		1.54	ОК
1.2.5	Work allocation	Fully Met	1.54	1.54	https://pharma ceuticals.gov.i n/work-allocat on-and- committees		1.54	ОК
1.3	Procedure followed in decision making proce	ss [Section	4(1)(b)(iii)]				
1.3.1	Process of decision making Identify key decision making points	Fully Met	1.54	1.54	https://pharma ceuticals.gov.i n/proactive- disclosure		1.54	https://pharma ceuticals.gov.i n/channel- submission

Sr. No	Details of disclosure	Category	Marks	Obtained	Remarks	Auditor	Auditor	Auditor
				Mark		Category	Marks	Remarks/URL
								OK
1.3.2	Final decision making authority	Fully Met	1.54	1.54	https://pharma ceuticals.gov.i n/proactive- disclosure		1.54	https://pharma ceuticals.gov.i n/channel- submission
1.3.3	Related provisions, acts, rules etc.	Fully Met	1.54	1.54	https://pharma ceuticals.gov.i n/proactive- disclosure		1.54	ОК
1.3.4	Time limit for taking a decisions, if any	Fully Met	1.54	1.54	https://pharma ceuticals.gov.i n/proactive- disclosure	-	0.77	https://pharma ceuticals.gov.i n/proactive- disclosure
1.3.5	Channel of supervision and accountability	Fully Met	1.54	1.54	https://pharma ceuticals.gov.i n/proactive- disclosure	•	1.54	https://pharma ceuticals.gov.i n/channel- submission
1.4	Norms for discharge of functions[Section 4(1)(b)(iv)]						
1.4.1	Nature of functions/ services offered	Fully Met	1.54	1.54	https://darpg.g ov.in/sites/def ault/files/CSM OP2022.pdf		1.54	https://darpg.g ov.in/sites/def ault/files/CSM OP2022.pdf
1.4.2	Norms/ standards for functions/ service delivery	Fully Met	1.54	1.54	https://darpg.g ov.in/sites/def ault/files/CSM OP2022.pdf		1.54	https://darpg.g ov.in/sites/def ault/files/CSM OP2022.pdf
1.4.3	Process by which these services can be accessed	Fully Met	1.54	1.54	https://darpg.g ov.in/sites/def ault/files/CSM OP2022.pdf		1.54	https://darpg.g ov.in/sites/def ault/files/CSM OP2022.pdf
1.4.4	Time-limit for achieving the targets	Fully Met	1.54	1.54	https://darpg.g ov.in/sites/def		1.54	https://darpg.g ov.in/sites/def

Sr. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
					ault/files/CSM OP2022.pdf			ault/files/CSM OP2022.pdf
1.4.5	Process of redress of grievances	Fully Met	1.54	1.54	https://darpg.g ov.in/sites/def ault/files/CSM OP2022.pdf		1.54	https://darpg.g ov.in/sites/def ault/files/CSM OP2022.pdf
1.5	Rules, regulations, instructions manual and	records for dis	chargin	g function	s[Section 4(1)	(b)(v)]		
1.5.1	Title and nature of the record/ manual /instruction.	Fully Met	1.92	1.92	https://pharma ceuticals.gov.i n/proactive- disclosure	Fully Met	1.92	ОК
1.5.2	List of Rules, regulations, instructions manuals and records.	Partially Met	1.92	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure	-	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure
1.5.3	Acts/ Rules manuals etc.	Fully Met	1.92	1.92	https://pharma ceuticals.gov.i n/proactive- disclosure		1.92	https://pharma ceuticals.gov.i n/proactive- disclosure
1.5.4	Transfer policy and transfer orders	Fully Met	1.92	1.92	https://pharma ceuticals.gov.i n/proactive- disclosure	•	0.96	OK. Copy of updated transfer Orders in Deprtment may be uploaded and made available
1.6	Categories of documents held by the authori	ty under its co	ontrol[Se	ection 4(1)				
1.6.1	Categories of documents	Fully Met	3.85	3.85	https://pharma ceuticals.gov.i n/proactive-		3.85	https://pharma ceuticals.gov.i n/proactive-

Sr. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
					disclosure			disclosure
1.6.2	Custodian of documents/categories	Fully Met	3.85	3.85	https://pharma ceuticals.gov.i n/proactive- disclosure	•	3.85	https://pharma ceuticals.gov.i n/proactive- disclosure
1.7	Boards, Councils, Committees and other Bodi	es constitu	ted as par	rt of the Pu	blic Authority	[Section 4(1)	(b)(viii)]	
1.7.1	Name of Boards, Council, Committee etc.	Fully Met	0.96	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure	Fully Met	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure
1.7.2	Composition	Fully Met	0.96	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure	-	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure
1.7.3	Dates from which constituted	Fully Met	0.96	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure	-	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure
1.7.4	Term/ Tenure	Fully Met	0.96	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure	•	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure
1.7.5	Powers and functions	Fully Met	0.96	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure		0.96	https://pharma ceuticals.gov.i n/proactive- disclosure
1.7.6	Whether their meetings are open to the public?	Fully Met	0.96	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure	-	0.48	Specific details are not available
1.7.7	Whether the minutes of the meetings are open to the public?	Fully Met	0.96	0.96	https://pharma ceuticals.gov.i	•	0.96	https://pharma ceuticals.gov.i

Sr. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
					n/proactive-			n/proactive-
4 7 0			0.00	0.00	disclosure		0.40	disclosure
1.7.8	Place where the minutes if open to the public are available?	Fully Met	0.96	0.96	https://pharma ceuticals.gov.i n/proactive- disclosure	-	0.48	https://pharma ceuticals.gov.i n/proactive- disclosure
1.8	Directory of officers and employees[Section 4	(1) (b) (ix)]						
1.8.1	Name and designation	Fully Met	3.85	3.85	https://pharma ceuticals.gov.i n/whos-who	· ·	3.85	https://pharma ceuticals.gov.i n/whos-who
1.8.2	Telephone , fax and email ID	Fully Met	3.85	3.85	https://pharma ceuticals.gov.i n/whos-who	· ·	3.85	https://pharma ceuticals.gov.i n/whos-who
1.9	Monthly Remuneration received by officers &	employees	including	system of	compensatio	n[Section 4(1) (b) (x)]	
1.9.1	List of employees with Gross monthly remuneration	Fully Met	3.85	3.85	https://pharma ceuticals.gov.i n/proactive- disclosure	Fully Met	3.85	https://pharma ceuticals.gov.i n/proactive- disclosure
1.9.2	System of compensation as provided in its regulations	Fully Met	3.85	3.85	https://pharma ceuticals.gov.i n/proactive- disclosure		3.85	https://pharma ceuticals.gov.i n/proactive- disclosure
1.10	Name, designation and other particulars of pu	blic informa	ation offic	ers[Sectio	n 4(1) (b) (xvi)			
1.10.1	Name and designation of the public information officer (PIO), Assistant Public Information officer (APIO) & Appellate Authority	Fully Met	3.85	3.85	https://pharma ceuticals.gov.i n/cpios		3.85	https://pharma ceuticals.gov.i n/cpios
1.10.2	Address, telephone numbers and email ID of each designated official.	Fully Met	3.85	3.85	https://pharma ceuticals.gov.i n/cpios		3.85	https://pharma ceuticals.gov.i n/cpios
1.11	No. Of employees against whom Disciplinary	action has b	been prop	osed/ take	n(Section 4(2))		
1.11.1	No. of employees against whom disciplinary action has been (i) Pending for Minor penalty or	Fully Met	3.85	3.85	https://pharma ceuticals.gov.i		0	No Information is

Sr. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
	major penalty proceedings				n/proactive- disclosure	5 9		available
1.11.2	(ii) Finalised for Minor penalty or major penalty proceedings	Fully Met	3.85	3.85	https://pharma ceuticals.gov.i n/proactive- disclosure		0	No Information is available
1.12	Programmes to advance understanding of RT	(Section 26)						
1.12.1	Educational programmes	Not Met	1.92	0	empty	Not Met	0	No Information is available
1.12.2	Efforts to encourage public authority to participate in these programmes	Not Met	1.92	0	empty	Not Met	0	No Information is available
1.12.3	Training of CPIO/APIO	Not Met	1.92	0	empty	Not Met	0	No Information is available
1.12.4	Update & publish guidelines on RTI by the Public Authorities concerned	Fully Met	1.92	1.92	https://pharma ceuticals.gov.i n/rti-act		1.92	https://pharma ceuticals.gov.i n/rti-act
1.13	Transfer policy and transfer orders[F No. 1/6/2	011- IR dt. 1	5.4.2013					
1.13.1	Transfer Policy And Transfer Orders[F No. 1/6/2011- IR Dt. 15.4.2013]	Fully Met	7.69	7.69	https://pharma ceuticals.gov.i n/proactive- disclosure		3.85	Details of orders are not available
Total			100	93		100	79	
2	Budget and Programme							
2.1	Budget allocated to each agency including all 4(1)(b)(xi)]	plans, prop	osed exp	enditure a	nd reports on	disbursemen	ts made e	etc.[Section
2.1.1	Total Budget for the public authority	Fully Met	10	10.00	https://pharma ceuticals.gov.i n/detailed-de mand-grants	•	10.00	https://pharma ceuticals.gov.i n/budget-and- expenditure

Sr. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
2.1.2	Budget for each agency and plan & programmes	Fully Met	10	10.00	https://pharma ceuticals.gov.i n/detailed-de mand-grants		10.00	https://pharma ceuticals.gov.i n/budget-and- expenditure
2.1.3	Proposed expenditures	Fully Met	10	10.00	https://pharma ceuticals.gov.i n/detailed-de mand-grants		10.00	https://pharma ceuticals.gov.i n/budget-and- expenditure
2.1.4	Revised budget for each agency, if any	Fully Met	10	10.00	https://pharma ceuticals.gov.i n/detailed-de mand-grants		10.00	https://pharma ceuticals.gov.i n/budget-and- expenditure
2.1.5	Report on disbursements made and place where the related reports are available	Fully Met	10	10.00	https://pharma ceuticals.gov.i n/detailed-de mand-grants		10.00	https://pharma ceuticals.gov.i n/budget-and- expenditure
2.2	Foreign and domestic tours(F.No. 1/8/2012- IR	dt. 11.9.201	2)					
2.2.1	Budget	Fully Met	16.67	16.67	https://pharma ceuticals.gov.i n/proactive- disclosure		16.67	https://pharma ceuticals.gov.i n/proactive- disclosure
2.2.2	Foreign and domestic Tours by ministries and officials of the rank of Joint Secretary to the Government and above, as well as the heads of the Department (a) Places visited, (b) The period of visit, (c) The number of members in the official delegation, (d) Expenditure on the visit	Fully Met	16.67	16.67	https://pharma ceuticals.gov.i n/proactive- disclosure		16.67	https://pharma ceuticals.gov.i n/proactive- disclosure
2.2.3	Information related to procurements- (a) Notice/tender enquires, and corrigenda if any thereon, (b) Details of the bids awarded comprising the names of the suppliers of goods/ services being procured, (c) The works contracts	Fully Met	16.67	16.67	https://pharma ceuticals.gov.i n/proactive- disclosure		16.67	https://pharma ceuticals.gov.i n/proactive- disclosure

Sr. No	Details of disclosure	Category	Marks	Obtained Mark			Auditor Marks	Auditor Remarks/URL
	concluded – in any such combination of the above-and, (d) The rate/ rates and the total amount at which such procurement or works contract is to be executed.							
2.3	Manner of execution of subsidy programme [S	Section 4(i)(b)	(xii)]					
2.3.1	Name of the programme of activity	Not Applicable	90	0	empty	Not Met	0	No mention . If Nil it may be mentioned for information of citizens in Manual
2.3.2	Objective of the programme	Not Applicable	e0	0	empty	Not Applicable	e0	NA
2.3.3	Procedure to avail benefits	Not Applicable	e0	0	empty	Not Applicable	e0	NA
2.3.4	Duration of the programme/ scheme	Not Applicable	e0	0	empty	Not Applicable	90	NA
2.3.5	Physical and financial targets of the programme	Not Applicable	e0	0	empty	Not Applicable	90	NA
2.3.6	Nature/ scale of subsidy /amount allotted	Not Applicable	e0	0	empty	Not Applicable	90	NA
2.3.7	Eligibility criteria for grant of subsidy	Not Applicable	e0	0	empty	Not Applicable	90	NA
2.3.8	Details of beneficiaries of subsidy programme (number, profile etc)	Not Applicable	90	0	empty	Not Applicable	90	NA
2.4	Discretionary and non-discretionary grants [F.	. No. 1/6/2011	IR dt. 1	5.04.2013]				
2.4.1	Discretionary and non-discretionary grants/ allocations to State Govt./ NGOs/other institutions	Fully Met	25	25.00	https://pharma ceuticals.gov.i n/proactive- disclosure	•	25.00	https://pharma ceuticals.gov.i n/proactive- disclosure
2.4.2	Annual accounts of all legal entities who are provided grants by public authorities	Fully Met	25	25.00	https://pharma ceuticals.gov.i n/proactive- disclosure		25.00	https://pharma ceuticals.gov.i n/proactive- disclosure
2.5	Particulars of recipients of concessions, perm	its of authoriz	zations	granted by	y the public au	thority[Sectio	n 4(1) (b) (xiii)]
2.5.1	Concessions, permits or authorizations granted by public authority	Fully Met	25	25.00	https://pharma ceuticals.gov.i n/proactive-	•	25.00	https://pharma ceuticals.gov.i n/proactive-

Sr. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
					disclosure			disclosure.
2.5.2	For each concessions, permit or authorization granted - (a) Eligibility criteria, (b) Procedure for getting the concession/ grant and/ or permits of authorizations, (c) Name and address of the recipients given concessions/ permits or authorizations, (d) Date of award of concessions/ permits of authorizations	Fully Met	25	25.00	https://pharma ceuticals.gov.i n/proactive- disclosure		12.50	Details are not available
2.6	CAG & PAC paras [F No. 1/6/2011- IR dt. 15.4.2	2013]						
2.6.1	CAG and PAC paras and the action taken reports (ATRs) after these have been laid on the table of both houses of the parliament.		50	50.00	https://pharma ceuticals.gov.i n/proactive- disclosure	-	25.00	Details are not available
Total			250	250		256	213	
Total 3	Publicity Band Public interface		250	250		256	213	
	Particulars for any arrangement for consultati		epresenta	ation by the		the public in		o the
3			epresenta	ation by the	6/2011-IR dt. 19 https://pharma ceuticals.gov.i n/proactive-	the public in 5.04.2013] Fully Met		o the https://pharma ceuticals.gov.i n/proactive- disclosure
3 3.1	Particulars for any arrangement for consultati formulation of policy or implementation there Relevant Acts, Rules, Forms and other documents which are normally accessed by	of [Section Fully Met Fully Met	epresenta 4(1)(b)(vi	ation by the i)] [F No 1/	6/2011-IR dt. 1 https://pharma ceuticals.gov.i	the public in 5.04.2013] Fully Met	relation t	https://pharma ceuticals.gov.i n/proactive-

Sr. No	Details of disclosure	Category	Marks	Obtained Mark	Remarks	Auditor Category	Auditor Marks	Auditor Remarks/URL
3.1.4	Public- private partnerships (PPP)- Detailed project reports (DPRs)	Fully Met	2.78	2.78	https://pharma ceuticals.gov. n/proactive- disclosure		1.39	Details are not there
3.1.5	Public- private partnerships (PPP)- Concession agreements.	Fully Met	2.78	2.78	https://pharma ceuticals.gov. n/proactive- disclosure		1.39	Details are not there
3.1.6	Public- private partnerships (PPP)- Operation and maintenance manuals	dFully Met	2.78	2.78	https://pharma ceuticals.gov. n/proactive- disclosure	-	1.39	Details are not there
3.1.7	Public- private partnerships (PPP) - Other documents generated as part of the implementation of the PPP	Fully Met	2.78	2.78	https://pharma ceuticals.gov. n/proactive- disclosure		1.39	Details are not there
3.1.8	Public- private partnerships (PPP) - Information relating to fees, tolls, or the other kinds of revenues that may be collected under authorisation from the government	Fully Met	2.78	2.78	https://pharma ceuticals.gov. n/proactive- disclosure	-	1.39	Details are not there
3.1.9	Public- private partnerships (PPP) -Information relating to outputs and outcomes	Fully Met	2.78	2.78	https://pharma ceuticals.gov. n/proactive- disclosure	•	1.39	Details are not there
3.1.10	Public- private partnerships (PPP) - The process of the selection of the private sector party (concessionaire etc.)	Fully Met	2.78	2.78	https://pharma ceuticals.gov. n/proactive- disclosure		2.78	Details are not there
3.1.11	Public- private partnerships (PPP) - All payment made under the PPP project	Fully Met	2.78	2.78	https://pharma ceuticals.gov. n/proactive- disclosure	•	1.39	Details are not there

Sr. No	Details of disclosure	Category	Marks	Obtained	Remarks	Auditor	Auditor	Auditor
				Mark		Category	Marks	Remarks/URL
3.2	Are the details of policies / decisions, which a	ffect public,	informed	to them[S	Section 4(1) (c)]		
3.2.1	Publish all relevant facts while formulating important policies or announcing decisions which affect public to make the process more interactive - Policy decisions/ legislations taken in the previous one year	Fully Met	16.67	16.67	https://pharma ceuticals.gov. n/proactive- disclosure		16.67	https://pharma ceuticals.gov.i n/proactive- disclosure
3.2.2	Publish all relevant facts while formulating important policies or announcing decisions which affect public to make the process more interactive - Outline the Public consultation process	Fully Met	16.67	16.67	https://pharma ceuticals.gov. n/proactive- disclosure	•	16.67	https://pharma ceuticals.gov.i n/proactive- disclosure
3.2.3	Publish all relevant facts while formulating important policies or announcing decisions which affect public to make the process more interactive- Outline the arrangement for consultation before formulation of policy	Fully Met	16.67	16.67	https://pharma ceuticals.gov. n/proactive- disclosure	•	16.67	https://pharma ceuticals.gov.i n/proactive- disclosure
3.3	Dissemination of information widely and in su	ch form and	manner	which is e	asily accessib	le to the pul	olic [Sectio	n 4(3)]
3.3.1		Fully Met	50	50.00	https://pharma ceuticals.gov. n/proactive- disclosure	Fully Met	50.00	https://pharma ceuticals.gov.i n/proactive- disclosure
3.4	Form of accessibility of information manual/ h	andbook[Se	ction 4(1)(b)]				
3.4.1	Information manual/handbook available in Electronic format	Fully Met	25	25.00	https://pharma ceuticals.gov. n/proactive- disclosure	•	25.00	https://pharma ceuticals.gov.i n/proactive- disclosure . Need to be updated
3.4.2 3.5	Information manual/handbook available in Printed format Whether information manual/ handbook availa		25	25.00	https://pharma ceuticals.gov. n/proactive- disclosure	•	25.00	https://pharma ceuticals.gov.i n/proactive- disclosure

Sr. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
3.5.1	List of materials available Free of cost	Fully Met	25	25.00	https://pharma ceuticals.gov.i n/proactive- disclosure	-	12.50	https://pharma ceuticals.gov.i n/proactive- disclosure . Details are not there
3.5.2	List of materials available At a reasonable cost of the medium	Fully Met	25	25.00	https://pharma ceuticals.gov.i n/proactive- disclosure		12.50	https://pharma ceuticals.gov.i n/proactive- disclosure. Details are not available
Total			250	250		250	214	
4	E-Governance							
4.1	Language in which Information Manual/Handb	ook Availab	ole [F No.	1/6/2011-IF	R dt. 15.4.2013]		
4.1.1	English	Fully Met	14.29	14.29	https://pharma ceuticals.gov.i n/proactive- disclosure		14.29	https://pharma ceuticals.gov.i n/proactive- disclosure
4.1.2	Vernacular/ Local Language	Fully Met	14.29	14.29	https://pharma ceuticals.gov.i n/proactive- disclosure		14.29	https://pharma ceuticals.gov.i n/proactive- disclosure
4.2	When was the information Manual/Handbook	last updated	l?[F No. 1	/6/2011-IR	dt 15.4.2013]			
4.2.1	Last date of Annual updation	Fully Met	28.57	28.57	https://pharma ceuticals.gov.i n/proactive- disclosure	-	14.29	To be updated regularly
4.3	Information available in electronic form[Section	on 4(1)(b)(xi	v)]					
4.3.1	Details of information available in electronic form	Fully Met	9.52	9.52	https://pharma ceuticals.gov.i n/proactive-	-	9.52	https://pharma ceuticals.gov.i n/proactive-

Name/ title of the document/record/ other information	Fully Met	9.52	Mark 9.52	disclosure	Category	Marks	Remarks/URL disclosure
	Fully Met	9.52	0.52				disclosure
	Fully Met	9.52	0.52	• • • •			
			9.52	https://pharma ceuticals.gov.i n/proactive- disclosure	-	9.52	https://pharma ceuticals.gov.i n/proactive- disclosure
Location where available	Fully Met	9.52	9.52	ceuticals.gov.i n/proactive- disclosure	-	9.52	https://pharma ceuticals.gov.i n/proactive- disclosure . More link to be provided for easy access of the citizens
Particulars of facilities available to citizen fo	r obtaining in	formatio	n[Section 4	l(1)(b)(xv)]			
Name & location of the faculty	Fully Met	7.14	7.14			7.14	https://pharma ceuticals.gov.i n/proactive- disclosure
Details of information made available	Fully Met	7.14	7.14			7.14	https://pharma ceuticals.gov.i n/proactive- disclosure
Working hours of the facility	Fully Met	7.14	7.14			7.14	https://pharma ceuticals.gov.i n/proactive- disclosure
Contact person & contact details (Phone, fax email)	Fully Met	7.14	7.14		•	7.14	https://pharma ceuticals.gov.i n/proactive- disclosure
	Particulars of facilities available to citizen for Name & location of the faculty Details of information made available Working hours of the facility Contact person & contact details (Phone, fax email)	Particulars of facilities available to citizen for obtaining in Name & location of the faculty Fully Met Details of information made available Fully Met Working hours of the facility Fully Met Contact person & contact details (Phone, fax email) Fully Met	Particulars of facilities available to citizen for obtaining information Name & location of the faculty Fully Met Petails of information made available Fully Met Vorking hours of the facility Fully Met Contact person & contact details (Phone, fax email) Fully Met	Particulars of facilities available to citizen for obtaining information[Section 4 Name & location of the faculty Fully Met 7.14 7.14 Details of information made available Fully Met 7.14 7.14 Working hours of the facility Fully Met 7.14 7.14 Contact person & contact details (Phone, fax Fully Met 7.14 7.14	Location where availableFully Met9.529.52https://pharmaceuticals.gov.in/proactive-disclosureParticulars of facilities available to citizen for obtaining informationSection 4(1)(b)(xv)]Name & location of the facultyFully Met7.147.14Name & location of the facultyFully Met7.147.14Details of information made availableFully Met7.147.14Working hours of the facilityFully Met7.147.14Contact person & contact details (Phone, fax email)Fully Met7.147.14Name and availableFully Met7.147.14Name and availableFully Met7.147.14Name and availableFully Met7.147.14Norking hours of the facilityFully Met7.147.14Contact person & contact details (Phone, fax email)Fully Met7.147.14Name and availableFully Met7.147.14Contact person & contact details (Phone, fax email)Fully Met7.147.14Name and availableFully Met7.147.14 </td <td>Location where availableFully Met9.529.52https://pharma Fully Met ceuticals.gov.i n/proactive- disclosureParticulars of facilities available to citizen for obtaining information[Section 4(1)(b)(xv)]Name & location of the facultyFully Met7.147.14https://pharma Fully Met ceuticals.gov.i n/Details of information made availableFully Met7.147.14https://pharma Fully Met ceuticals.gov.i n/Working hours of the facilityFully Met7.147.14https://pharma Fully Met ceuticals.gov.i n/Contact person & contact details (Phone, fax email)Fully Met7.147.14https://pharma Fully Met ceuticals.gov.i n/</td> <td>Location where availableFully Met9.529.52https://pharmaFully Met ceuticals.gov.i n/proactive- disclosure9.52Particulars of facilities available to citizen for obtaining information Name & location of the facultyFully Met7.147.14https://pharmaFully Met ceuticals.gov.i n/7.14Details of information made availableFully Met7.147.14https://pharmaFully Met ceuticals.gov.i n/7.14Working hours of the facilityFully Met7.147.14https://pharmaFully Met ceuticals.gov.i n/7.14Contact person & contact details (Phone, fax email)Fully Met7.147.14https://pharmaFully Met ceuticals.gov.i n/7.14</td>	Location where availableFully Met9.529.52https://pharma Fully Met ceuticals.gov.i n/proactive- disclosureParticulars of facilities available to citizen for obtaining information[Section 4(1)(b)(xv)]Name & location of the facultyFully Met7.147.14https://pharma Fully Met ceuticals.gov.i n/Details of information made availableFully Met7.147.14https://pharma Fully Met ceuticals.gov.i n/Working hours of the facilityFully Met7.147.14https://pharma Fully Met ceuticals.gov.i n/Contact person & contact details (Phone, fax email)Fully Met7.147.14https://pharma Fully Met ceuticals.gov.i n/	Location where availableFully Met9.529.52https://pharmaFully Met ceuticals.gov.i n/proactive- disclosure9.52Particulars of facilities available to citizen for obtaining information Name & location of the facultyFully Met7.147.14https://pharmaFully Met ceuticals.gov.i n/7.14Details of information made availableFully Met7.147.14https://pharmaFully Met ceuticals.gov.i n/7.14Working hours of the facilityFully Met7.147.14https://pharmaFully Met ceuticals.gov.i n/7.14Contact person & contact details (Phone, fax email)Fully Met7.147.14https://pharmaFully Met ceuticals.gov.i n/7.14

r. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
4.5.1	Grievance redressal mechanism	Fully Met	3.57	3.57	www.pgportal. gov.in	Fully Met	3.57	Okay
4.5.2	Details of applications received under RTI and information provided	Fully Met	3.57	3.57	https://pharma ceuticals.gov.i n/proactive- disclosure		3.57	https://rtionlin e.gov.in/
4.5.3	List of completed schemes/ projects/ Programmes	Fully Met	3.57	3.57	https://pharma ceuticals.gov.i n/schemes	•	3.57	Okay
4.5.4	List of schemes/ projects/ programme underway	Fully Met	3.57	3.57	https://pharma ceuticals.gov.i n/schemes		3.57	https://pharma ceuticals.gov.i n/schemes. Okay
4.5.5	Details of all contracts entered into including name of the contractor, amount of contract and period of completion of contract	Not Met	3.57	0	empty	Not Met	0	Not available
4.5.6	Annual Report	Fully Met	3.57	3.57	https://pharma ceuticals.gov.i n/annual- report	•	3.57	https://pharma ceuticals.gov.i n/annual- report
4.5.7	Frequently Asked Question (FAQs)	Not Met	3.57	0	empty	Not Met	0	Not available
4.5.8	Any other information such as - (a) Citizen's Charter, (b) Result Framework Document (RFD), (c) Six monthly reports on the , (d) Performance against the benchmarks set in the Citizen's Charter	Fully Met	3.57	3.57	https://pharma ceuticals.gov.i n/citizen- charter		3.57	https://pharma ceuticals.gov.i n/citizen- charter
4.6	Receipt & Disposal of RTI applications & appe	eals [F.No 1/	6/2011-IR	dt. 15.04.2	2013]			
4.6.1	Details of applications received and disposed			14.29	https://pharma ceuticals.gov.i n/proactive- disclosure		7.15	Details are not there
4.6.2	Details of appeals received and orders issued	Fully Met	14.29	14.29	https://pharma	Partially Met	7.15	Details are no

Sr. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
					ceuticals.gov.i n/proactive- disclosure			there
4.7	Replies to questions asked in the parliament[Section 4(1)	(d)(2)]					
4.7.1	Details of questions asked and replies given	Fully Met	28.57	28.57	https://pharma ceuticals.gov.i n/proactive- disclosure		28.57	https://pharma ceuticals.gov.i n/proactive- disclosure
Total			200	193		200	164	
5	Information as may be prescribed							
5.1	Such other information as may be prescribed	-				1	-	
5.1.1	Name & details of - (a) Current CPIOs & FAAs, (b) Earlier CPIO & FAAs from 1.1.2015	Fully Met	20	20.00	https://pharm aceuticals.gov .in/cpios	•	20.00	https://pharma ceuticals.gov.i n/cpios
5.1.2	Details of third party audit of voluntary disclosure -(a) Dates of audit carried out , (b) Report of the audit carried out	Fully Met	20	20.00	https://pharma ceuticals.gov.i n/proactive- disclosure	•	10.00	All details are not available
5.1.3	Appointment of Nodal Officers not below the rank of Joint Secretary/ Additional HoD - (a) Date of appointment, (b) Name & Designation of the officers	Fully Met	20	20.00	https://pharma ceuticals.gov.i n/proactive- disclosure		10.00	No mention
5.1.4	Consultancy committee of key stake holders for advice on suo-motu disclosure - (a) Dates from which constituted, (b) Name & Designation of the officers	Not Met	20	0	empty	Not Met	0	Not available
5.1.5	Committee of PIOs/FAAs with rich experience in RTI to identify frequently sought information under RTI - (a) Dates from which constituted, (b) Name & Designation of the Officers	Not Met	20	0	empty	Not Met	0	Not available
Total			100	60		100	40	
6	Information Disclosed on own Initiative							

Sr. No	Details of disclosure	Category	Marks	Obtained Mark		Auditor Category	Auditor Marks	Auditor Remarks/URL
6.1	Item / information disclosed so that public ha	ave minimum	resort to	use of RT		0,		
6.1.1	Item / information disclosed so that public have minimum resort to use of RTI Act to obtain information	Fully Met	25	25.00	https://pharma ceuticals.gov.i n/proactive- disclosure	,	12.50	2
6.2	Guidelines for Indian Government Websites Secretariat Manual of Office Procedures (CS Personnel, Publ	• •	•		•			
6.2.1	Whether STQC certification obtained and its validity	Fully Met	12.5	12.50	https://pharma ceuticals.gov.i n/proactive- disclosure	-	12.50	Okay
6.2.2	Does the website show the certificate on the Website?	Fully Met	12.5	12.50	https://pharma ceuticals.gov.i n/proactive- disclosure		12.50	Okay
Total			50	50		50	38	